The multitarget approach of PPT-14, addressing PTP1B inhibition, AR inhibition, and oxidative stress mitigation, positions it as a promising therapeutic alternative for the management of diabetes and diabetes-associated complications. The gene discussed is PTPN1; the disease is diabetes mellitus.